

REPLACED BY
ART 34 AMDT

CLAIMS

1. Nucleic acid sequence encoding an *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 7.
2. Nucleic acid sequence encoding a 28 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 3.
3. Nucleic acid sequence encoding a 25 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 5.
4. Nucleic acid sequence encoding a 31 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 1.
5. Nucleic acid sequence encoding a 30 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 9.

6. Nucleic acid sequence encoding a 24 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 11.
7. Nucleic acid sequence encoding a 65 kD *Ostertagia ostertagi* protein or a part of said nucleic acid sequence that encodes an immunogenic fragment of said protein, said nucleic acid sequence or said part thereof having at least 85%, preferably 90 %, more preferably 95 % homology with the nucleic acid sequence of the *Ostertagia ostertagi* protein gene as depicted in SEQ ID NO: 13.
8. DNA fragment comprising a nucleic acid sequence according to claim 1-7.
9. Recombinant DNA molecule comprising a nucleic acid sequence according to claim 1-7 or a DNA fragment according to claim 8, under the control of a functionally linked promoter.
10. Live recombinant carrier comprising a nucleic acid sequence according to claim 1-7, a DNA fragment according to claim 8 or a recombinant DNA molecule according to claim 9.
11. Host cell comprising a nucleic acid sequence according to claim 1-7, a DNA fragment according to claim 8, a recombinant DNA molecule according to claim 9 or a live recombinant carrier according to claim 10.
12. An *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 8.
13. A 28 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 4.

14. A 25 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 6.
15. A 31 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 2.
16. A 30 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 10.
17. A 24 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 12.
18. A 65 kD *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, characterized in that said protein or immunogenic fragment thereof has a sequence homology of at least 90%, preferably 92 %, more preferably 94% to the amino acid sequence as depicted in SEQ ID NO: 14.
19. An *Ostertagia ostertagi* protein or an immunogenic fragment of said protein, according to claim 12-18, characterized in that said protein or immunogenic fragment is encoded by a nucleic acid sequence according to claim 1-7.
20. An *Ostertagia ostertagi* protein or an immunogenic fragment thereof, according to claim 12-19 for use in a vaccine.

21. Use of a nucleic acid sequence according to claim 1-7, a DNA fragment according to claim 8, a recombinant DNA molecule according to claim 9, a live recombinant carrier according to claim 10, a host cell according to claim 11 or a protein according to claim 12-19 or an immunogenic fragment thereof for the manufacturing of a vaccine for combating *Ostertagia ostertagi* infection.
22. Vaccine for combating *Ostertagia ostertagi* infection, characterized in that said vaccine comprises at least one *Ostertagia ostertagi* protein or an immunogenic fragment of said protein according to claim 12-19 and a pharmaceutically acceptable carrier.
23. Vaccine for combating *Ostertagia ostertagi* infection, characterized in that said vaccine comprises a nucleic acid sequence according to claim 1-7, a DNA fragment according to claim 8, a recombinant DNA molecule according to claim 9, a live recombinant carrier according to claim 10 or a host cell according to claim 11 and a pharmaceutically acceptable carrier.
24. Vaccine for combating *Ostertagia ostertagi* infection, characterized in that said vaccine comprises antibodies against a protein or an immunogenic fragment thereof according to claim 12-19 and a pharmaceutically acceptable carrier.
25. Vaccine according to claim 22-24, characterized in that said vaccine comprises an adjuvant.
26. Vaccine according to claim 22-25, characterized in that said vaccine comprises an additional antigen derived from a virus or micro-organism pathogenic to cattle, an antibody against said antigen or genetic information encoding said antigen and/or a pharmaceutical component.
27. Vaccine according to claim 26, characterized in that said virus or micro-organism pathogenic to cattle is selected from the group of Bovine Herpesvirus, Bovine Viral Diarrhea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, *Pasteurella haemolytica*, Bovine Respiratory Syncytial Virus, *Theileria* sp., *Babesia* sp., *Trypanosoma* species, *Anaplasma* sp., *Neospora caninum*, *Staphylococcus aureus*, *Streptococcus agalactiae*, *Mycoplasma*, *E. coli*, *Enterobacter*, *Klebsiella*, *Citrobacter*, *Cryptosporidium*, *Salmonella* and *Streptococcus dysgalactiae*.

28. Method for the preparation of a vaccine according to claim 22-27, said method comprising the admixing of a nucleic acid sequence according to claim 1-7, a DNA fragment according to claim 8, a recombinant DNA molecule according to claim 9, a live recombinant carrier according to claim 10, a host cell according to claim 11, a protein according to claim 12-19 or antibodies against a protein according to claim 12-19, and a pharmaceutically acceptable carrier.
29. A diagnostic kit comprising suitable detection means and a nucleic acid sequence according to claim 1-7 or a primer fragment thereof, or a protein according to claim 12-19, or an immunogenic fragment of said protein, or antibodies that are reactive with a protein according to claim 12-19.